Why Manufacturing Is the New Competitive Edge in Cell and Gene Therapy
April 16, 2026
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Eytan Abraham, the Chief Commercial and Technology Officer at Minaris Advanced Therapies, to dive into how pharma companies can choose the right CDMO partners, the future of cell and gene therapy manufacturing, and the hard-earned lessons behind building sustainable, high-performance organizations in one of the most complex areas of medicine.
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Eytan Abraham, the Chief Commercial and Technology Officer at Minaris Advanced Therapies, to dive into how pharma companies can choose the right CDMO partners, the future of cell and gene therapy manufacturing, and the hard-earned lessons behind building sustainable, high-performance organizations in one of the most complex areas of medicine.
What You’ll Learn:
- Why CDMO selection is your single highest-impact business decision
- How to evaluate a CDMO partner when your company's future depends on the choice
- The counterintuitive advantage of cell therapy manufacturing over small molecules
- Why manufacturing has gone from an afterthought to a critical strategic decision
- Why in-house manufacturing is almost always the wrong capital allocation, except for one scenario
- How investor composition and board experience directly predict success or failure
Eytan Abraham is the Chief Commercial and Technology Officer at Minaris Advanced Therapies, a global leader in cell and gene therapy manufacturing and biosafety testing. Eytan brings over a decade of experience across cell and gene therapy development, CDMOs, and biotech innovation, with leadership roles spanning organizations like Lonza and Resilience. His unique perspective across public, venture-backed, and private equity-backed environments gives him a rare, 360-degree view of what it takes to build, scale, and optimize advanced therapy manufacturing.
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
Episode Resources:
Episode Resources:
Pharma Sessions is handcrafted by our friends over at: fame.so